Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07003425 · ClinicalTrials.gov registry record · Phase 2

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis, sponsored by Apogee Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
350
Enrollment target
20
Study locations

NCT07003425 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Apogee Therapeutics. The registered enrollment target is 350 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07003425, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Apogee Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
350 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.

Conditions Studied

Atopic Dermatitis

Interventions

  • DRUG APG777

Study Locations (20)

Florida

  • Investigational Site - Coral Gables
  • Investigational Site - Jacksonville
  • Investigational Site - Margate

Texas

  • Investigational Site - Dallas
  • Investigational Site - Frisco
  • Investigational Site - San Antonio

California

  • Investigational Site - Fountain Valley
  • Investigational Site - Los Angeles

Michigan

  • Investigational Site - Detroit
  • Investigational Site - Troy

Ohio

  • Investigational Site - Boardman
  • Investigational Site - Mason

Georgia

  • Investigational Site - Douglasville

Illinois

  • Investigational Site - Skokie

Kentucky

  • Investigational Site - Bowling Green

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2025-05-14
Est. Completion 2029-12
Phase Phase 2

Sponsor

Apogee Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07003425

The ClinicalTrials.gov registry entry for NCT07003425 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (42% lower). The listed sponsor is Apogee Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which APG777 is the first listed.

NCT07003425 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Texas, California.

Frequently Asked Questions

What is clinical trial NCT07003425 about?

NCT07003425 is a clinical study titled "A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis". This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will ...

What is the current status of trial NCT07003425?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2025-05-14. Estimated completion is 2029-12.

What conditions does trial NCT07003425 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT07003425?

The interventions under investigation include: APG777 (DRUG).

Who is sponsoring clinical trial NCT07003425?

This trial is sponsored by Apogee Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07003425 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.